Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.

PloS one - 1 Jan 2015

Hiratsuka Masahiro, Yamashita Hiroshi, Akai Fumika, Hosono Hiroki, Hishinuma Eiji, Hirasawa Noriyasu, Mori Takahiro

Abstract excerpt

Dihydropyrimidinase (DHP) is the second enzyme in the catabolic pathway of uracil, thymine, and chemotherapeutic fluoropyrimidine agents such as 5-fluorouracil (5-FU). Thus, DHP deficiency might be associated with 5-FU toxicity during fluoropyrimidine chemotherapy. We performed genetic analyses o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amidohydrolases
Share to Antineoplastic Agents
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Codon, Nonsense

Share to Colonic Neoplasms

Share to Mutation, Missense

Share to Uracil

Source

Open in PubMed Open full text

Identifiers

PMID: 25915935
DOI: 10.1371/journal.pone.0124818
PMCID: PMC4411063

Genes

DPYS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25915935-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms of dihydropyrimidinase in a Japanese patient with capecitabine-induced toxicity.PMID 25915935Read ↗

Novel single nucleotide polymorphisms of the dihydropyrimidinase gene (DPYS) in Japanese individuals.Semantic proximity Read ↗

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.Semantic proximity Read ↗

Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population.Semantic proximity Read ↗

[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].Semantic proximity Read ↗

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.Semantic proximity Read ↗

DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer PatientsSemantic proximity Read ↗

Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups.Semantic proximity Read ↗

Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.Semantic proximity Read ↗

DPYD (Dihydropyrimidine Dehydrogenase) Variant c.2194G>A (Normal Metabolizer) with Severe Toxicities in Patients Treated with Fluoropyrimidine Based Regimens. A first Case Report from Bihar, IndiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.